Fibroheal Woundcare, a silk proteins-based medical devices startup, has raised Rs 6.3 crore in a pre-Series A funding round. The investment comes from existing promoters and a new group of investors, including surgeons, medical professionals, and bankers. The company has also secured an additional commitment of Rs 10 crore from existing and some new investors.
Founded in 2017 by Vivek Mishra and Bharat Tandon, Fibroheal plans to use the funds to ramp up its go-to-market strategy, expand its workforce, and invest in its medical device product pipeline. The startup’s product portfolio includes foams, mesh, and powders designed to treat various wounds, such as acute, chronic, traumatic, post-operative, and non-healing wounds.
Fibroheal ramps up product expansion
Fibroheal’s products are used in more than 500 hospitals across 19 states in India and are available on various e-commerce platforms. The company’s product line is used to heal different types of wounds, including bed sores and infected C-section wounds. Investor KK Narayanan, who previously co-founded Metahelix Life Sciences and Kottaram Agrofoods, said, “Fibroheal is well-positioned to become a major player in the fast-growing wound care segment with its innovative silk-based technology, strong leadership, and skilled team.”
Fibroheal has previously raised funds from existing promoters Telama Investments, CCAMP, and KITVEN.
The company’s focus on innovation and growth has helped it expand its footprint in the wound care market, bringing advanced and effective wound management solutions to healthcare providers and patients. With this fresh investment, Fibroheal aims to scale up its market reach, recruit more personnel, and develop a robust future pipeline of medical devices. The startup plans to utilize the economic multiplier potential of silk and other biomaterials to make a significant impact in the healthcare industry.
